The Impact of Innovation, Investment and Global Cooperation on Healthcare

On Monday, September 20th, C3 Summit International, in collaboration with the U.S. Department of State; United Nations; and the U.S. Chamber of Commerce, cordially Invites you to attend the 11th Annual C3 US-Arab Healthcare & Business Summit: "The Impact of Innovation, Investment and Global Cooperation on Healthcare & Business"

Never before has a C3 US-Arab Healthcare & Business Summit been so timely. The 2021 conference will address the many new opportunities in lessons learned from the pandemic in business, science, healthcare, big data, cancer, community trends, telemedicine and more.

Don't miss this unique opportunity to hear from specialists in many of the world's leading healthcare institutions and government organizations. With a "netcast" reach of more than 3 million potential global viewers, and more than 500 attendees from over 53 countries, we definitely anticipate another epic C3 Summit. So act now!

The C3 US-Arab Healthcare & Business Summit is honored to also announce the:

8:00-8:45am: REGISTRATION & CONTINENTAL BREAKFAST

7:30-9:15 am: SUMMIT CHAIR:

Dr Ghassan Abou-Alfa, Memorial Sloan Kettering Cancer Center, USA

WELCOMING REMARKS:

Mr. David Jackson, Founder & Chairman, Solitaire Partners, USA; Chief Executive Officer, Istihmar World, 2006-2010, Dubai

9:15-10:00 am: KEYNOTE ADDRESS:

"Lessons Learned from Confronting Pandemics Globally and COVID19 Domestically"

KEYNOTE SPEAKER:

Ambassador, Dr. Deborah L. Birx, White House Coronavirus Task Force (retired) & 2021 "C3 Humanitarian Award" Recipient

Dr. Deborah L. Birx, MD is a world-renowned physician scientists and expert on HIV/AIDS and infectious diseases and a diplomat who served as a special representative for global health diplomacy. Most recently, Dr. Birx served on the White House Coronavirus Task Force from Mar. 2020 to Jan. 2021. Her four-decade-long career has focused on HIV/AIDS, TB/HIV, immunology, vaccine research, global pandemics and global health. As the U.S. Global AIDS Coordinator for presidents Barack Obama and Donald Trump, Dr. Birx oversaw the implementation of the 6 B/yr U.S. President's Emergency Plan for AIDS Relief (PEPFAR), the largest commitment by any nation to combat a single disease in history, as well as all U.S. government engagement with the Global Fund to Fight AIDS, Tuberculosis, and Malaria. Serving as the U.S. Special Representative for Global Health Diplomacy, she aligned the U.S. Government's diplomacy with foreign assistance programs that address global health challenges and accelerate progress toward achieving an AIDS-free generation; ending preventable child and maternal deaths; and preventing, detecting, and responding to infectious disease threats.

In 1980, Dr. Birx began her career with the Department of Defense (DoD) first as a Medical Resident in Internal Medicine, Fellow in Clinical Immunology and then as a military-trained clinician in immunology, focusing on HIV/AIDS vaccine research. From 1985-1989 she served as an Assistant Chief of the Hospital Immunology Service at Walter Reed Army Medical Center. Through her professionalism and leadership in the field, she served as the Director of the U.S. Military HIV Research Program (USMHRP) at the Walter Reed Army Institute of Research from 1996-2005. Dr. Birx began and led one of the most influential HIV vaccine trials in history (known as RV 144, or the Thai trial), which provided the first supporting evidence of any vaccine's potential effectiveness in preventing HIV infection. During this time, she also rose to the rank of Colonel, bringing together the Navy, Army, and Air Force in a new model of cooperation - increasing the efficiency and effectiveness of the U.S. military's HIV/AIDS efforts through inter-and intra-agency collaboration. Then known as Colonel Birx, she was awarded two prestigious U.S. Meritorious Service Medals and the Legion of Merit Award for her groundbreaking research, leadership and management skills during her tenure at DoD.

From 2005-2014, Dr. Birx served as the Director of the Centers for Disease Control and Prevention's (CDC) Division of Global HIV/AIDS (DGHA) in the CDC Center for Global Health. As DGHA Director, she utilized her leadership ability, superior technical skills, and passion to achieve tremendous health impact. She successfully led the implementation of CDC's PEPFAR programs around the world and managed an annual budget of more than $1.5 billion. Dr. Birx was responsible for all of the agency's global HIV/AIDS activities, including providing oversight to more than 400 staff at headquarters, over 1,500 staff in the field, and more than 45 country and regional offices in Africa, Asia, the Caribbean, and Latin America. Recognized for her distinguished and dedicated commitment to building local capacity and strengthening quality laboratory health services and systems in Africa, in 2011, Dr. Birx received a Lifetime Achievement Award from the African Society for Laboratory Medicine. In 2014, CDC honored her leadership in advancing the agency's HIV/AIDS response with the highly prestigious William C. Watson, Jr. Medal of Excellence, the highest honor bestowed by the CDC.

Dr. Birx received her medical degree from the Hershey School of Medicine, Pennsylvania State University. She trained in internal medicine and basic and clinical immunology at the Walter Reed Army Medical Center and the National Institutes of Health. Dr. Birx is board certified in internal medicine, allergy and immunology, and diagnostic and clinical laboratory immunology. She has published over 240 manuscripts in peer-reviewed journals, authored nearly a dozen chapters in scientific publications, as well as developed and patented vaccines. She has received multiple awards for her work.

10:10-11:10 am: "Kingdom of Saudi Arabia: Creating a New Global Benchmark in Community Healthcare"

One-on-One Interview: Dr. Maliha Hashmi, Prominent Health Leader, Kingdom of Saudi Arabia; One of Top Seven Female Health Leaders, MENA Region

The Kingdom of Saudi Arabia is about building the first cognitive healthcare system, where world-class technology is fueled with data and intelligence to interact seamlessly with its population, so that health and well-being can be integrated into a holistic lifestyle. KSA will establish a new benchmark toward a culture shift of proactive prevention, with medical intervention as needed, all powered by the latest technologies. In order to provide this state-of-the art healthcare, KSA has built its holistic healthcare vision around five global benchmarks of health and wellbeing: mental, physical, virtual, social, and emotional support.

11:20-12:20 pm:"The Role of Big Data/IOT in Public Healthcare and Emergency Preparedness Including Energy & Defense"

Panel Moderator: Dr. Rabi Hanna, Director of the Pediatric Bone Marrow Transplantation, Department of Pediatric Hematology and Oncology, Cleveland Clinic Children’s Hospital, USA

Mr. Paul Doherty, President & CEO, IFMA Fellow, DFC Senior Fellow, TDG - the digit group, inc., USA

Dr. Ann Aerts, MD, Head, The Novartis Foundation, Novartis International AG, Switzerland

Mr. Danny E. Sebright, President, U.S.- U.A.E. Business Council, USA

Dr. Rafael A. Irizarry, Professor, Biostatistics and Computational Biology, Dana-Farber Cancer Institute, USA

There has been plenty of press and opinions of the future of healthcare and the role wellness plays into creating this future. The numerous descriptions of things like Digital Twins, Blockchain, Telemedicine and other emerging technologies can create an anxiety among practitioners, researchers, administrators, and institutions that entered an industry and community with a very traditional approach to assist patients, clients and guests that now has to face digital transformation as part of their reality.

Join us for an exploration of our industry’s new reality that includes how you and our industry’s people acknowledge and adapt to digital transformation, prepare for the sea change in value recognition, and position ourselves for success. Our healthcare/wellness industry is colliding with the world of technology, entertainment, and the built environment at a rapid pace. Our panel will provide insights into how best to position your role in the future of the healthcare and wellness industry.

12:20-2:00 pm LUNCH & KEYNOTE SPEAKER

Mr. Mick Merritt, Chief Operating Officer, Penn Signature Services, Penn Medicine, USA

Luncheon Address: His Excellency Shaikh Abdulla R. Al Khalifa, Ambassador of the Kingdom of Bahrain to the United States

2021 Recipient: HRH Prince Salman bin Hamad Al Khalifa, Crown Prince, Deputy Supreme Commander and Prime Minister, Kingdom of Bahrain

As an avenue to cementing bilateral relations, the C3 Leadership Award recognizes the importance of an individual's initiatives and interests based on “social and commercial diplomacy,” thereby making an invaluable, enduring contribution to both their country and global community.

With these personal achievements in mind, and a focus on increasing commercial ties between the US and the Arab world, from the personal interchange that it involves to the mutual economic interests that it develops, leadership is critical to encouraging dialogue and imagination, in order to explore new opportunities that will grow regional and global prosperity. The end result will pave the path to increased progress for economic engagement between all global markets.

2:00-3:00 pm:"The Pandemic's Impact on Current & Future Global Healthcare"

Panel Moderator: Dr. Maan Fares, MD, Vice Chairman, Global Patient Services, The Cleveland Clinic

Dr. Gabi Hanna, MD, Executive Director, Duke Translational Research Unit; Associate Director, Duke Cancer Institute, Surgical Facility; VP, American Remote Health, USA

Dr. Nureldin Satti, Ambassador to the United States, Sudanese Embassy, Washington, DC, Sudan

Dr Ghassan Abou-Alfa, Memorial Sloan Kettering Cancer Center, USA

Dr. David T. Martin, Associate Medical Director, International Patient Center; Vice Chair, Network Development & Innovative Care Solutions, Brigham & Women's Hospital, USA

The pandemic's disruptions to the healthcare industry were immediate and acute. While U.S. hospitals usually have plans for dealing with mass casualties and natural disasters, few had contemplated, much less planned for, the arrival of a global pandemic that was the biggest threat to American lives since the 1918 Spanish flu. One of the most immediate disruptions was the collapse of supply lines for personal protective equipment (PPE). The industry learned that it had “too significant a reliance on a supply chain based in just one part of the world, i.e. China. Another challenge was finding the space and beds to accommodate the influx of COVID-19 patients, but an even greater problem was staffing those beds. Also unexpected was the impact on America's healthcare workers and the amount of misinformation and conflicting messaging they were asked to address, which left people unsure of whom to listen and how to protect themselves from the virus.

Finally, with all the unfortunate disruptions, there was the one most welcomed disruption: record setting vaccine discoveries and distributions to the global population. Also, the pandemic pushed healthcare systems into an arena previously occupied primarily by government and local health departments: public health. When healthcare systems provided drive-through testing facilities, created web-based symptom checkers or call centers so people could ask questions about the virus, launched vaccine clinics, or advised schools and businesses about how to safely reopen, they were providing public health services.

3:10-4:10 pm:"Telemedicine: Global Trends in a New Norm"

Panel Moderator: Cynthia Gonzalez, Executive Director of the International Patient Services Program at Cook Children’s Health Care System, USA

Hon. Lawrence Silverman, US Ambassador (ret), US Embassy, Kuwait, USA

Dr. Djaoued Bedjaoui, MD, Senior Medical Advisor for Health, Embassy of the United Arab Emirates, Washington, D.C., USA, UAE

Mr. Joseph DeVivo, President, Hospital & Health Systems, Teladoc Health, Inc., USA

Dr. Claus Jensen, PhD, Chief Innovation Officer, Teladoc Health, USA

The most lasting new healthcare norm promoted by the global pandemic is likely to be telemedicine. Before the coronavirus, the public’s response to the idea of visiting a doctor via computer or cell phone was lukewarm at best, and neither Medicare nor private health insurance companies were interested in covering such visits. But when the pandemic hit, people adopted telehealth out of necessity. Same thing for providers. They needed to see their patients and telemedicine became the safest and the most efficient way to provide remote healthcare. As a result, the pandemic led the way for government and insurance companies to recognize and pay for telehealth for patients.

4:20-5:20 pm:"Cancer Prevention and Treatment: Patient Centered Care Delivery and Cutting-Edge Personalized Therapies"

Panel Moderator: Mr Robert Steven Kramarz, Founder & Executive Director, Jericho Project & Intelliversity, USA

Dr Sapna Syngal, MD, MPH, Director, GI Cancer Genetics and Prevention Program, Medical Oncology, Dana-Farber Cancer Institute; Professor, Medicine, Harvard Medical School, USA

M.Sc. Polona Šafarič Tepeš, Visiting Scientist, Cold Spring Harbor Laboratory, Researcher at the University of Ljubljana; Director, Girls in Science for SDG, Royal Academy of Science Int. Trust (RASIT), Ljubljana, Slovenia

Health systems are still working on developing and adopting patient centered care and personalized therapies that will be necessary to facilitate the widespread utilization of personalized medicine, which differs significantly from the one-size-fits-all approaches to health care that have dominated medicine for most of human history. Guided by this patient centered care, physicians have begun to embrace a new way of treating cancer patients called personalized medicine. Also referred to as precision medicine, this evolving field involves the use of diagnostic tests to determine which personalized therapies will work best for each patient. By combining the data from those tests with an individual’s medical history, circumstances, and values, health care providers can develop targeted approaches to cancer prevention and treatments.

5:20-5:45 pm: Closing Remarks:

"The Impact of Innovation, Investment and Global Cooperation on Healthcare & Business"

Dr. Jason Dictenberg, PhD, Founder & CEO, AccelBio, USA

Dr. Salam Al-Bader, Founder & CEO, Albader Ventures Inc; Deputy Chairman, Global House of Bahrain, Kuwait

Host or Publisher C3 Summit International